Role of CXCR2 Ligands/CXCR2 Biological Axis in Pancreatic Cancer

Mayo Clinic

Status: Completed

Conditions: Chronic Pancreatitis; Pancreatic Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT00851955

07-000099

Details and patient eligibility

About

The investigators hypothesize that the CXCR2 ligands/CXCR2 biological axis plays an important role in promoting angiogenesis in PC; and that the genetic changes and the microenvironment of the tumor regulate the expression of CXCR2 ligands/CXCR2 in PC in order to potentiate their angiogenic phenotype. A corollary of this hypothesis is that the cell surface receptors (CXCR2) and the intracellular signaling pathways that mediate the angiogenic responses induced by ELR+ CXC-chemokines are potential targets for novel therapeutic interventions in PC.

Enrollment: 150 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Normal subjects - No documented clinical history of pancreatic diseases supported by at least 1 negative imaging test. (EUS, Ct scan or MRI)
• Chronic pancreatitis - Documented diagnosis of moderate to advanced chronic supported bpancreatitisy at least 1 positive imaging test. (EUS, Ct scan or MRI)
• Pancreatic Cancer - Documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.

Exclusion criteria

• Exclusion criteria will include age younger than 18 yrs, pregnancy, previous pancreatic or gastric resection, and inability to tolerate routine endoscopy with conscious sedation

Trial design

150 participants in 3 patient groups

1. Normal pancreas patients

Description:

Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).

2. Chronic pancreatitis patients

Description:

Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).

3. Pancreatic cancer patients

Description:

Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.